Companies · Pharmaceuticals

LivFul Inc.

TEMPLE · Pharmaceuticals

Diligence memoA one-page analyst read on LivFul Inc. — recommendation, valuation, rhythm, risks.
$10.1M
Total raised · real
4
Rounds
2.0×
Latest step-up
Top 46%
Sector rank · raised
Series A
Latest stage · inferred · Mon Dec 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

LivFul Inc. looks under-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.04× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era.
Active
  • Last raise 7 mo ago; this sector typically re-raises about every 13 months.
  • Raising on or ahead of the sector's normal rhythm.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

LivFul Inc. is one of 1613 Pharmaceuticals companies tracked from TEMPLE. By capital raised it ranks mid-pack (ahead of 55% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
2
Investors (latest)
2025-12-08
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeries A · 2021-03-22 Raised $6.7M (real) Modeled valuation $149M (est)$6.7M$149MSeries A2021Series A · 2022-05-01 Raised $3.1M (real) Modeled valuation $42M (est)$3.1M$42MSeries A2022Pre-Seed · 2022-05-01 Raised $750K (real) Modeled valuation $12M (est)$750K$12MPre-Seed2022Series A · 2024-05-24 Raised $125K (real) Modeled valuation $675K (est)$125K$675KSeries A2024Series A · 2025-12-08 Raised $250K (real) Modeled valuation $676K (est)$250K$676KSeries A2025+$3.1M+$750K+$125K+$250KCumulative $11M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.7M · 2021
Series A extension$3.1M · 2022
Bridge · Series A-stage$750K · 2022smaller follow-on
Series A extension$125K · 2024
Series A extension$250K · 2025

Stages are modeled from round size (public records carry no series label). No record for: Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$676K
Base estimate est.
$286K
Conservative case
$1.0M
Upside case
$1.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Series A · modeled $149.3M · 2021-03-222021Series A · modeled $42.3M · 2022-05-01Pre-Seed · modeled $12.1M · 2022-05-01Series A · modeled $675K · 2024-05-24Series A · modeled $676K · 2025-12-082025
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
46%
Survival probability
25% low · 63% high
1.57×/yr
Annual markup
1.97×/yr upside case
0.6 yr
Elapsed time used
0.6 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
14 mo
Avg between rounds
$2.2M/yr
Capital velocity
5.3 yr
On record since
2021
First round
5
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.3× above median
This company$10.1M
Sector median$8.1M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.0× of median
This company$250K
Sector median$5.2M
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$676K
Sector median$76.1M

Raised more than 55% of sector peers (real $). Modeled value above 2% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #37 of 37.

This companyCohort peer
$100K$1.0M$10.0M$100.0M$1.0M$10.0M$100.0MCapital raised (log)Incannex Healthcare Inc. · Series A Raised $12.5M · modeled $47.3M (est)Retension Pharmaceuticals, Inc. · Series A Raised $22.4M · modeled $44.1M (est)Eikonoklastes Therapeutics, Inc. · Series A Raised $25.0M · modeled $43.9M (est)Phoenicis Therapeutics, Inc. · Series A Raised $23.8M · modeled $38.6M (est)Pharmaceutical Resource Technology, Inc. · Series A Raised $10.0M · modeled $37.5M (est)Cristcot LLC · Series A Raised $31.6M · modeled $37.4M (est)Akava Therapeutics Inc. · Series A Raised $30.1M · modeled $37.1M (est)Zetagen Therapeutics, Inc. · Series A Raised $26.1M · modeled $36.6M (est)Biofrontera Inc. · Series A Raised $58.4M · modeled $36.4M (est)D&D Pharmatech Inc. · Series A Raised $10.8M · modeled $36.0M (est)Incyclix Bio, LLC · Series A Raised $26.2M · modeled $35.4M (est)Pharmazz, Inc. · Series A Raised $31.7M · modeled $34.5M (est)LivFul Inc. (this company) Raised $10.1M · modeled $676K (est)LivFul Inc.
CompanyStageRaised · realValue · estvs peer med.
Incannex Healthcare Inc.Series A$12.5M$47.3M2.93×
Retension Pharmaceuticals, Inc.Series A$22.4M$44.1M2.73×
Eikonoklastes Therapeutics, Inc.Series A$25.0M$43.9M2.72×
Phoenicis Therapeutics, Inc.Series A$23.8M$38.6M2.39×
Pharmaceutical Resource Technology, Inc.Series A$10.0M$37.5M2.32×
Cristcot LLCSeries A$31.6M$37.4M2.32×
Akava Therapeutics Inc.Series A$30.1M$37.1M2.30×
Zetagen Therapeutics, Inc.Series A$26.1M$36.6M2.27×
Biofrontera Inc.Series A$58.4M$36.4M2.25×
D&D Pharmatech Inc.Series A$10.8M$36.0M2.23×
Incyclix Bio, LLCSeries A$26.2M$35.4M2.20×
Pharmazz, Inc.Series A$31.7M$34.5M2.14×
LivFul Inc. this companySeries A$10.1M$676K0.04×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.7M2021-03-22$30.3M$149.3M90%
Series A$3.1M2022-05-01$14.1M$42.3M90%
Pre-Seed$750K2022-05-01$4.2M$12.1M90%
Series A$125K2024-05-24$568K$675K90%
Series A$250K2025-12-08$1.1M$676K90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.7M2021-03-22
    • First recorded raise — entered as Series A.
    • 60 investors on this round.
  2. Series A$3.1M2022-05-01
    • Raised 13 mo later, in step with the ~13 mo sector norm.
    • Round 2.1× smaller than the prior — bridge or down round.
    • 13 investors on this round.
  3. Pre-Seed$750K2022-05-01
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.1× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  4. Series A$125K2024-05-24
    • Raised again after 25 mo — slower than the ~13 mo sector norm.
    • Round 6.0× smaller than the prior — bridge or down round.
    • 1 investor on this round.
  5. Series A$250K2025-12-08
    • Raised 18 mo later, in step with the ~13 mo sector norm.
    • Round 2.0× larger than the prior — scaling up.
    • 2 investors on this round.
Intelligence
2027 ~Q1
Modeled next raise · ~14mo cadence
$500K
Modeled next size est.range $325K$800K
2.0×
Last step-up
$2.2M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
MICHAEL NORMAN3 other2021-03
ANDREW BARLOW2 other2025-12
Carl Thong2025-12
Dave Rae2021-03
Francis Yip2021-03
Hogan Bassey2021-03
John Manwell2021-03
Kevin Engel2024-05
Kris Maynard2024-05
Matt Elsberry2021-03
Wesley Lyons2022-05
Yaw Nsarkoh2024-05
Registry & provenance

LivFul Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1845848
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Tonix Pharmaceuticals Holding Corp.PharmaceuticalsSeries A$10.3M$9.7Msame sector · same stage
Coeptis Therapeutics Holdings, Inc.PharmaceuticalsSeries A$10.3M$12.8Msame sector · same stage
CURE PHARMACEUTICAL CorpPharmaceuticalsSeries A$9.9M$10.0Msame sector · same stage
Invirsa, Inc.PharmaceuticalsSeries A$9.8M$9.2Msame sector · same stage
Aspargo Laboratories, Inc.PharmaceuticalsSeries A$9.7M$3.1Msame sector · same stage
Aarvik Therapeutics, Inc.PharmaceuticalsSeries A$9.5M$5.1Msame sector · same stage
Intezyne Technologies, Inc.PharmaceuticalsSeries A$9.3M$14.9Msame sector · same stage
Seneca Therapeutics, Inc.PharmaceuticalsSeries A$11.0M$6.9Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Livible, Inc.OtherSeries A$46.2M80%
LivOnyx Inc.Other Health CarePre-Seed$14.0M78%
eMindful Inc.Other Health CareSeed$10.2M78%
DeliverCareRX, Inc.PharmaceuticalsSeries A$37.2M77%
Diffusion Pharmaceuticals Inc.PharmaceuticalsSeries C$26.3M77%
Revere Pharmaceuticals Inc.PharmaceuticalsSeed$13.6M77%
LP Investors, LLCPharmaceuticalsSeries B$1.4B77%
MEDPhlow, LLCPharmaceuticalsPre-Seed$6.6M77%
Frequently asked
How much funding has LivFul Inc. raised?
LivFul Inc. has raised approximately $10.1M in disclosed capital across 4 recorded financing rounds, aggregated from public filings.
What is LivFul Inc.'s estimated valuation?
Provath's modeled valuation for LivFul Inc. is approximately $676K (modeled range $286K–$1.0M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is LivFul Inc. at?
LivFul Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon Dec 08.
What does LivFul Inc. do and where is it based?
LivFul Inc. operates in the Pharmaceuticals sector, based in TEMPLE.
Explore related

See where LivFul Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at LivFul Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.